

Dennis M. Erb, Ph.D.  
Senior Director  
Regulatory Affairs

Merck & Co., Inc.  
P.O. Box 4, BLA-20  
West Point PA 19486  
Tel 610 397 7597  
215 652 5000  
Fax 610 397 2516

2774 '01 JAN -5 19:16

January 4, 2001

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane  
Rm. 1061  
Rockville, MD 20852



**RE: [Docket No. 00D-1562] Draft Guidance for Industry on Cancer Drug and Biological Products—Clinical Data in Marketing Applications**


Merck & Co., Inc. is a leading worldwide, human health product company. Through a combination of the best science and state-of-the-art medicine, Merck's R & D pipeline has produced many of the important pharmaceutical products on the market, today.

Merck's product portfolio is diverse and includes products which are indicated for use within the patient population intended to be most affected by this *Draft Guidance for Industry on Cancer Drug and Biological Products—Clinical Data in Marketing Applications* (hereafter referred to as *The Draft Guidance*). We, therefore, are qualified by this experience to comment on *The Draft Guidance*.

In the course of bringing research candidates through oncology clinical trials, Merck's physicians would rely on guidance such as this for advice on how best to collect, format, analyze and present clinical data for review by FDA's Centers.<sup>1</sup> It is with that perspective in mind, that Merck's oncology team has reviewed *The Draft Guidance* and finds it generally well thought-out advice, that is investigator-friendly and reasonable for the purpose intended.

We understand that *The Draft Guidance* will provide a general framework for the evaluation of all critical data collected on oncology trials within the context of current medical practice. However, our experience in registration of product applications indicates that no amount of guidance on the format and content of applications can substitute for the essential dialogue that must take place between applicants and regulators, particularly when the intended patient condition is life-threatening. Therefore, we recommend that *The Draft Guidance* would be improved by some discussion about the need for, and FDA's support for a continuous dialogue between sponsors and regulators to ensure efficiency and concurrence throughout a development program where there may be a smaller margin for error than usual.

Sincerely,

  
Dennis M. Erb, Ph.D.  
Senior Director  
Regulatory Affairs

<sup>1</sup> Centers = Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)

00D-1562

C1

192

200

**FedEx** *USA Airbill*  
Express
FedEx  
Tracking  
Number

8257 3275 8222

**1 From** This portion can be removed for Recipient's records.

Date 1/4/01 FedEx Tracking Number 825732758222

Sender's Name Dennis M. Erb, Ph.D. Phone 610 397-XXXX

Company MERCK SHARP & DOHME

Address 5 DENTRY PKWY EAST BIA-20

City BLUE BELL State PA ZIP 19422

Dept./Floor/Suite/Room

RECIPIENT: PEEL HERE

**2 Your Internal Billing Reference**
**3 To**  
 Recipient's Name Rockets Mgmt Branch HEA-305 Phone

Food & Drug Administration

Company

 Address 5630 Fishers Lane Room 1061

To "HOLD" at FedEx location, print FedEx address.

We cannot deliver to P.O. boxes or P.O. ZIP codes.

 City Rockville State MD ZIP 20852

Dept./Floor/Suite/Room



8257 3275 8222

FORM  
TX 40

0215

SPH43

Recipient's Copy

**4a Express Package Service**
☒ FedEx Priority Overnight  
 Next business morning

☐ FedEx Standard Overnight  
 Next business afternoon

**Packages up to 150 lbs.**  
 Delivery commitment may be later in some areas.  
☐ FedEx First Overnight  
 Earliest next business morning  
 delivery to select locations

☐ FedEx 2Day\*  
 Second business day

☐ FedEx Express Saver\*  
 Third business day

 \* FedEx Envelope/Letter Rate not available  
 Minimum charge: One-pound rate

**4b Express Freight Service**
☒ FedEx 1Day Freight\*  
 Next business day

☐ FedEx 2Day Freight  
 Second business day

**Packages over 150 lbs.**  
 Delivery commitment may be later in some areas.  
☐ FedEx 3Day Freight  
 Third business day

\* Call for Confirmation.

**5 Packaging**
☒ FedEx Envelope/Letter\*

☐ FedEx Pak\*

☐ Other Pkg.  
 Includes FedEx Box, FedEx  
 Tube, and customer pkg.

\* Declared value limit \$500

**6 Special Handling**
☐ SATURDAY Delivery

 Available only for FedEx Priority  
 Overnight and FedEx 2Day  
 to select ZIP codes

☐ SUNDAY Delivery

 Available only for FedEx Priority  
 Overnight to select ZIP codes

☐ HOLD Weekday  
 at FedEx Location

 Not available with  
 FedEx First Overnight

☐ HOLD Saturday  
 at FedEx Location  
 Available only for FedEx Priority  
 Overnight and FedEx 2Day  
 to select locations

Include FedEx address in Section 3.

 Does this shipment contain dangerous goods?  
 One box must be checked.

☐ No

☐ Yes

 As per attached  
 Shipper's Declaration

☐ Yes  
 Shipper's Declaration  
 not required

☐ Dry Ice  
 Dry Ice, 9, UN 1845

☐ Cargo Aircraft Only

Dangerous Goods cannot be shipped in FedEx packaging.

**7 Payment Bill to:**

Enter FedEx Acct No. or Credit Card No. below.

☒ Sender  
 Acct. No. in Section  
 1 will be billed.

☐ Recipient

☐ Third Party

☐ Credit Card

☐ Obtain Recip.  
 Acct. No.

☐ Cash/Check

Total Packages

Total Weight

Total Charges

Credit Card Auth.

\*Our liability is limited to \$100 unless you declare a higher value. See the FedEx Service Guide for details.

**8 Release Signature**

Sign to authorize delivery without obtaining signature.

 By signing you authorize us to deliver this shipment without obtaining a signature  
 and agree to indemnify and hold us harmless from any resulting claims.

**Questions? Visit our Web site at [www.fedex.com](http://www.fedex.com)**  
 or call 1-800-Go-FedEx® (800)463-3339.

SPS 1100 • Rev. Date 7/00 • Part #15501259 • ©1994-2000 FedEx • PRINTED IN U.S.A.

402